Courtney Miller

Courtney Miller, Ph.D.

Director Of Academic Affairs And Professor

Department: SR-ACADEMIC AFFAIRS
Business Phone: (561) 228-2958
Business Email: courtneymiller@ufl.edu

Accomplishments

Entrepreneur of the Year
2022 · BioFlorida
Co-Founder
2020 · Myosin Therapeutics (www.mysointherapeutics.com)
Elected Member
2020 · American College of Neuropsychopharmacology
Host
2018 · SFN Women in Neuroscience Luncheon, "Effective self-promotion"
Contributor
2017 · NIH Opioid Meeting Series, "Understanding the neurobiological mechanisms of pain"
Distinguished Speaker Award
2016 · UNC Department of Psychology and Neuroscience
PECASE (Presidential Early Career Award for Scientists and Engineers)
2016 ·
TSRI Outstanding Mentor Award
2015 ·
Associate Member
2014 · American College of Neuropharmacology
Most influential paper published by Neuron in 2007
2014 ·
Faculty of 1000 Selections
2013 ·
Faculty of 1000 Selections
2010 ·
Co-Organizer
2008 · Co-Organizer, SFN Social, Professional Women's Nexus (PWN), "Breaking barriers for young women in science"
Kauffman Fellow
2008 · Venture Capital Program
Co-Founder
2007 · Professional Women's Nexus (PWN)
Faculty of 1000 Selections
2007 ·
NIDA Young Investigator Award
2005 ·

Teaching Profile

Courses Taught
2023-2024
GMS6029 Brain Journal Club

Research Profile

The Miller Lab operates as two parallel, but integrated branches. The first takes an in vivo approach to the neurobiology of memory, connecting behavior, circuits and molecular and cellular mechanisms to identify potential therapeutic targets in neuropsychiatric disorders with a memory component, such as substance use disorders and PTSD. The complementary side of my lab is focused on assay development, drug discovery and development, seeded by our basic research efforts, with a focus on molecular nanomotors. The latter has also led us to apply our therapeutics to cancers, such as glioblastoma and pancreatic cancer, to simultaneously prevent tumor cell proliferation and invasion/metastasis.

Open Researcher and Contributor ID (ORCID)

0000-0001-8628-4902

Publications

2021
Discovery of Selective Inhibitors for In Vitro and In Vivo Interrogation of Skeletal Myosin II
ACS Chemical Biology. 16(11):2164-2173 [DOI] 10.1021/acschembio.1c00067.
2019
Social stress‐potentiated methamphetamine seeking
Addiction Biology. 24(5):958-968 [DOI] 10.1111/adb.12666. [PMID] 30105771.
2011
Forgot your HAT? CBP might be to blame.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 36(8):1543-4 [DOI] 10.1038/npp.2011.79. [PMID] 21673711.
2011
Stressed and depressed? Check your GDNF for epigenetic repression.
Neuron. 69(2):188-90 [DOI] 10.1016/j.neuron.2011.01.006. [PMID] 21262458.
2010
Cortical DNA methylation maintains remote memory.
Nature neuroscience. 13(6):664-6 [DOI] 10.1038/nn.2560. [PMID] 20495557.

Grants

Jul 2023 ACTIVE
The Impact of Individual Vulnerability to Stress on Alcohol and Drug Seeking
Role: Other
Funding: NATL INST OF HLTH NINDS
Apr 2023 ACTIVE
Drug Discovery for First-In-Class Myosin 10 Inhibitors as a Novel Target for Glioblastoma
Role: Principal Investigator
Funding: NATL INST OF HLTH NINDS
Jan 2023 ACTIVE
Intersection of causal neurodevelopmental disorder risk genes, cortical circuit function, and cognitive processing required for behavioral adaptions
Role: Co-Investigator
Funding: NATL INST OF HLTH NIMH
Sep 2022 ACTIVE
Neurodevelopmental Disorder Risk Gene Regulation of Intrinsic Membrane Excitability: A Rheostat that Tunes Dendritic Morphogenesis to Regulate Circuit Assembly During Development
Role: Principal Investigator
Funding: NATL INST OF HLTH NIMH
Apr 2022 – Dec 2022
Circuit-level substrates of ASD-related cognitive and behavioral impairments
Role: Principal Investigator
Funding: NATL INST OF HLTH NIMH
Apr 2022 ACTIVE
Integrated Platform for Discovery and Validation of Probes that Restore Protein Expression in Single-Gene Causes of Autism and Related Disorders
Role: Principal Investigator
Funding: NATL INST OF HLTH NIMH
Apr 2022 ACTIVE
Targeting Go and Grow in Glioblastoma
Role: Principal Investigator
Funding: MAYO CLINIC via NATL INST OF HLTH NINDS
Apr 2022 ACTIVE
Developing nonmuscle myosin II inhibitors for the treatment of glioblastoma
Role: Principal Investigator
Funding: NATL INST OF HLTH NINDS
Apr 2022 ACTIVE
Myosin II regulation of actin dynamics and the selective vulnerability of methamphetamine- and opioid-associated memory
Role: Principal Investigator
Funding: NATL INST OF HLTH NIDA
Apr 2022 ACTIVE
Preventing alcohol seeking with a nonmuscle myosin II inhibitor under clinical development
Role: Principal Investigator
Funding: NATL INST OF HLTH NIAAA
Apr 2022 – Jun 2023
Assessing the role of circRNAs in memory consolidation
Role: Co-Investigator
Funding: NATL INST OF HLTH NIMH
Apr 2022 – Mar 2023
Drug Discovery for First-In-Class Myosin 10 Inhibitors as a Novel Target for Glioblastoma
Role: Principal Investigator
Funding: NATL INST OF HLTH NINDS
Apr 2022 – Sep 2023
Development of AI-driven model for anti-SUD drug development based on neuronal plasticity
Role: Principal Investigator
Funding: VERISIM LIFE via NATL INST OF HLTH NIDA

Education

Technology Ventures Certification
2007-2009 · Collat School of Business
Ph.D. in Neurobiology
2005 · University of California, Irvine
Bachelor's of Science in Biopsychology
1999 · University of California, Santa Barbara

Contact Details

Phones:
Business:
(561) 228-2958
Emails:
Addresses:
Business Mailing:
130 SCRIPPS WAY BLDG 3B3
JUPITER FL 33458